A cancer-fighting cell therapy may offer new hope for people with severe rheumatoid arthritis, according to a study by Charité - Universitätsmedizin Berlin. The clinical trial, published in Nature Medicine, involved six patients whose rheumatoid arthritis had not responded to conventional treatments. After receiving the therapy, all participants experienced a significant reduction in disease activity. By the end of the follow-up period, three of the patients no longer needed medication for their condition, marking a major breakthrough in the treatment of this chronic autoimmune disease. Rheumatoid arthritis is a long-term condition in which the immune system attacks the body’s own joints, leading to inflammation, pain, and potential joint damage. Current treatments often manage symptoms and reduce inflammation but do not cure the disease. Many patients require ongoing use of anti-inflammatory drugs and immune-suppressing medications, which can have serious side effects. For some individuals, even newer therapies fail to provide sufficient relief, and these cases are referred to as "treatment-refractory" rheumatoid arthritis. The therapy tested in the study involves CAR T cells, a type of immune cell modified to target and destroy disease-causing B cells. B cells are part of the adaptive immune system and can produce harmful antibodies that attack the body’s own tissues in rheumatoid arthritis. These cells may persist in the lymph nodes, bone marrow, or joints, continuing to trigger inflammation. A key feature of these harmful B cells is a surface molecule called CD19. To help CAR T cells identify and eliminate them, researchers modify patients’ own immune cells to detect CD19, acting like a search sensor for these disease-driving cells. The first phase of the COMPARE trial showed highly encouraging results. All six patients experienced a marked decrease in disease activity. After up to one year of follow-up, three patients were in sustained remission without any medication. This outcome is particularly significant because existing treatments had previously failed to adequately control their symptoms. The therapy appeared to have a broader impact than just reducing inflammation. Researchers found that the modified immune cells reached deeper parts of the body, including the bone marrow, lymph nodes, and joint tissue, where disease-promoting B cells reside. Levels of autoantibodies linked to rheumatoid arthritis dropped sharply during follow-up visits. Importantly, antibodies from earlier vaccinations, such as those for chickenpox and tetanus, were still detectable, suggesting that the treatment did not erase the body’s ability to remember and respond to past infections. While the results are promising, CAR T-cell therapy for autoimmune diseases like rheumatoid arthritis is still experimental. Researchers have not yet gathered long-term data on its safety and effectiveness, and responses varied among the six participants. Some patients did not achieve full remission, and one experienced a return of symptoms after an initial period of improvement. The next phase of the trial will include ten more patients. Researchers plan to compare CAR T-cell therapy with an existing approved drug that also targets B cells. This comparison will help determine whether CAR T cells offer stronger or longer-lasting effects and whether they can truly reset immune memory. If these findings are confirmed in future studies, CAR T-cell therapy could provide a new treatment option for people with severe rheumatoid arthritis who have not responded to other treatments.